Image via Wikipedia
Yesterday morning the President of the Pontifical Council for Health, Cardinal Javier Lozano Barragan confirmed the Church’s position against embryonic stem cell research and for the use of adult stem cells. The cardinal touched upon the topic while responding to a question about the choice of the new American president to use federal funds to finance embryonic stem cell research. Cardinal Barragan, who was presenting the international conference, ‘The Church in the Cure of Sick Children’, which will take place at the Vatican from November 13-15, did not directly argue against President Obama “or
Scientists in the U.S. have made history as they have found a brand new, safer way to create embryonic stem cells.
Washington (dbTechno) – Scientists in the U.S. have made history as they have found a brand new, safer way to create embryonic stem cells.
There has been a great debate over the years due to safety concerns in regards to the development of embryonic stem cells, seen by many as the future of medicine.
This debate may now be put to rest though thanks to this new research announced this week.
Scientists at the University of California have found a potential new use for human embryonic stem cells: helping cancer patients recover the cognitive function lost when their brains are treated with radiation.
People with tumors in their head or neck often undergo radiation therapy after the cancer is surgically removed. Radiation helps kill malignant cells left behind. But it also can debilitate the hippocampus, the brain region responsible for learning, memory and processing of spatial information.
The researchers wondered whether embryonic stem cells could pick up the slack.
So they radiated the heads of 18 rats. Two days later, six of those
Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company — a sign of big pharmaceutical companies’ growing interest in stem cells (…)
The relatively small payment reflects that “it’s really early for cell therapy and there’s more research to be done,” said Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, a unit created by the company about 18 months ago to develop treatments based on stem cells (…)
Advanced Cell Technology, a leader in the field of regenerative medicine, today announced treatment of the first patient in its Phase 1/2 clinical trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, Jan. 20, at the Moorfields Eye Hospital in London by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The patient successfully underwent the procedure without any complications. ACT and Moorfields Eye Hospital received clearance in September from